Search
Research
Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western AustraliaBronchiolitis hospitalisations are a reasonable proxy for the timing of RSV detections, but may not fully capture the magnitude of RSV epidemics
Research
Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal peopleAustralian Aboriginal people have among the highest rates of invasive pneumococcal disease (IPD) worldwide. This paper investigates clinical diagnosis, risk...
Research
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high.
Research
COVID-19-Related Submission Priorities From the Journal of the Pediatric Infectious Diseases SocietyChristopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Research
Vaccine coverage in children born to migrant mothers in Australia: A population-based cohort studyOverall, infant immunisation coverage is currently >90% in Australia, but there are pockets of under-immunised children including children from migrant backgrounds.
Research
COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR)Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Research
Echinocandins in Pediatric Invasive Candidiasis and the Challenges of Antifungal Use in ChildrenIn pediatric invasive candidiasis (IC), epidemiology and risk factors differ compared to adults. Furthermore, the use of antifungals in children is challenging and requires consideration of availability and tolerability of formulations, pharmacokinetic and pharmacodynamic variations, and safety in different age groups.
Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.
Research
The STAMP RSV ProgramSTAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.